



Information on the Total Number of Voting Rights (Denominator)

Liege, Belgium, 6 May 2021 – 17:45 CEST – In accordance with article 15 of the Belgian Act of 2 May 2007 on the disclosure of major participations in issuers of which shares are admitted to trading on a regulated market and regarding miscellaneous provisions, Mithra Pharmaceuticals SA (the "Company" or "Mithra") announces the below information, following the issuance of 1,023,000 new shares on May 6, 2021 for a total amount of EUR 3,500,520 as the result of the exercise of 620 subscription rights (warrants) pursuant to the warrant plan initiated on March 2, 2015.

Following this capital increase's completion, the total number of shares issued by Mithra amounts to 43,737,097 outstanding shares carrying voting rights (compared to 42,714,097 outstanding shares previously). This number will be used for the calculation of the percentages of shareholdings.

Therefore, Mithra publishes the following updated information:

- **Share capital:** EUR 32,019,708.40
- **Total number of securities carrying voting rights:** 43,737,097 (all ordinary shares)
- **Total number of voting rights (= denominator):** 43,737,097 (all relating to ordinary shares)
- **Number of outstanding rights to subscribe to securities carrying voting rights not yet issued:**
 - 1,394,900 subscription rights issued on November 5, 2018, giving the right to subscribe for a total amount of 1,394,900 securities carrying voting rights¹ ;
 - 690,000 subscription rights issued on July 23, 2020, giving the right to subscribe for a total number of 690,000 shares in favor of LDA Capital Ltd pursuant to the transaction with LDA Capital Ltd announced by the Company on April 24, 2020²;
 - 300,000 subscription rights issued on September 7, 2020, giving the right to subscribe for a total number of 300,000 shares in favor of the lending shareholders, pursuant to the transaction with LDA Capital Ltd announced by the Company on April 24, 2020.
 - 74,717 subscription rights issued on November 20, 2020, giving the right to subscribe to a total number of 74,717 securities carrying voting rights³;

For more information, please contact:

Benoît Mathieu (IRO) : +32 473 35 80 18 - investorrelations@mithra.com

Maud Vanderthommen (Press) : +32 473 58 61 04 – press@mithra.com

¹ [Press release Mithra, 06/11/2018](#)

² [Press release Mithra, 24/04/2020](#)

³ [Press release Mithra, 20/11/2020](#)

About Mithra

Mithra (Euronext: MITRA) is a Belgian biotech company dedicated to transforming Women's Health by offering new choices through innovation, with a particular focus on contraception and menopause. Mithra's goal is to develop products offering better efficacy, safety and convenience, meeting women's needs throughout their life span. Mithra explores the potential of the unique native estrogen Estetrol in a wide range of applications in women health and beyond (Covid-19, neuroprotection...). Mithra also develops and manufactures complex therapeutics in the areas of contraception, menopause and hormone-dependent cancers. It offers partners a complete spectrum of research, development and specialist manufacturing at its technological platform Mithra CDMO. Active in more than 100 countries around the world, Mithra has an approximate headcount of 300 staff members and is headquartered in Liège, Belgium. www.mithra.com

Important information

The contents of this announcement include statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified by the use of forward-looking terminology, including the words "believes", "estimates," "anticipates", "expects", "intends", "may", "will", "plans", "continue", "ongoing", "potential", "predict", "project", "target", "seek" or "should", and include statements the Company makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. The Company's actual results may differ materially from those predicted by the forward-looking statements. The Company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.



News
Alerts

Subscribe to our mailing list on investors.mithra.com to receive our press releases by email or follow us on our social media :

[Linkedin](#) • [Twitter](#) • [Facebook](#)